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Background: Adhesins of pathogens recognise the glycans on the host cell and mediate adherence. They are also
crucial for determining the tissue preferences of pathogens. Currently, glyco-nanomaterials provide potential tool
for antimicrobial therapy. We demonstrate that properly glyco-tailored inclusion bodies can specifically bind
pathogen adhesins and release therapeutic substances.
Results: In this paper, we describe the preparation of tailored inclusion bodies via the conjugation of indicator
protein aggregated to form inclusion bodies with soluble proteins. Whereas the indicator protein represents a
remedy, the soluble proteins play a role in pathogen recognition. For conjugation, glutaraldehyde was used as
linker. The treatment of conjugates with polar lysine, which was used to inactivate the residual glutaraldehyde,
inhibited unwanted hydrophobic interactions between inclusion bodies. The tailored inclusion bodies specifically
interacted with the SabA adhesin from Helicobacter pylori aggregated to form inclusion bodies that were bound to
the sialic acids decorating the surface of human erythrocytes. We also tested the release of indicator proteins from
the inclusion bodies using sortase A and Ssp DNAB intein self-cleaving modules, respectively. Sortase A released
proteins in a relatively short period of time, whereas the intein cleavage took several weeks.
Conclusions: The tailored inclusion bodies are promising “nanopills” for biomedical applications. They are able to
specifically target the pathogen, while a self-cleaving module releases a soluble remedy. Various self-cleaving
modules can be enabled to achieve the diverse pace of remedy release.
Keywords: Nanopills, Pathogen targeting, Drug releaseBackground
The glycan chains that decorate cell surfaces mediate
various normal and pathological processes. They are also
responsible for host-pathogen interactions, as they are
used by various viruses, bacteria and parasites to pro-
mote the pathogenesis. Many pathogens express adhesins
on their surface, which are proteins capable of binding to
specific glycans. Adhesins play a very important role be-
cause the recognition of host-cell oligosaccharides and
their adherence is the crucial first step in the colonisation* Correspondence: nahalka@savba.sk
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reproduction in any medium, provided the orand/or invasion of a pathogen. Moreover, adhesins also
determine the tissue tropism of the corresponding patho-
gen [1,2]. Adhesins have been well-studied in the patho-
genesis of Helicobacter pylori. This worldwide bacterium
causes chronic gastritis, which may result in a peptic ulcer
or even in gastritic cancer and mucosa-associated lymph-
oid tissue lymphoma. Of at least six lectin-like adhesins
expressed by H. pylori, the most important for colonisa-
tion are BabA (blood group-binding adhesin) and SabA
(sialic acid-binding adhesin) [3-5]. SabA was selected as a
model adhesin for this study.
Recently, the idea has been proposed that the glycoen-
gineering of cell surfaces or the development of specific
glyco-nanomaterials will provide new tools for the thera-
peutic targeting of pathogenic or cancer cells [6,7]. Bac-
terial inclusion bodies (IBs) have a great potential to
serve as nanoparticles for these purposes. IBs are insolublel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cells during the over-expression of recombinant genes.
They have usually been considered to be waste byproducts
formed by unfolded or misfolded and thus biologically in-
active polypeptides [8]. The few first studies reporting the
enzymatic activity of IBs have been ignored [9,10]; how-
ever, the Villaverde group (2005) convincingly quantified
the biological activity of IBs and proposed an application
in bioprocesses [11]. It is already well-known that the for-
mation and disintegration of IBs in the cell is fully revers-
ible and a fraction of IBs is functional. More evidence is
appearing, indicating that IBs should not be removed from
the bioengineering process. On the contrary, it might be
even desirable to target protein production in order to
form IBs to be used as biomaterials for industry and bio-
medicine [8]. Several papers have been published regard-
ing the potential application of IBs in biocatalysis as
naturally immobilised enzymes with high stability and
good process properties [12-14]. At the same time, their
biological origin, mechanical stability and regulatable size
make IBs suitable nanomaterials for biomedicine [8].
With regards to biomedicine, the potential application
of IBs in tissue engineering and regenerative medicine
has been well-studied in the past few years. As it was
proven in bottom-up approaches to topographical engin-
eering, IBs decorating the surfaces favour mammalian
cell attachment and are capable of stimulating mamma-
lian cell proliferation [15,16]. Moreover, more progres-
sive opinions present IBs as potential “nanopills” for the
delivery of therapeutic proteins via their extra- or intra-
cellular release [17]. Various proteins, including chaper-
ones, enzymes and growth factors, aggregated to form
IBs were able to restore relevant missing cell functions
without any sign of cytotoxicity [17,18]. Liovic et al.
(2012) [19] demonstrated the delivery of a polymeric
cytoskeletal protein to epithelial cells in the form of sol-
uble IBs; these IBs also did not appear to be cytotoxic.
In general, IBs are naturally well-internalised by mam-
malian cells and it is not unusual for them to reach the
nucleus [17]. It is also very encouraging that orally admi-
nistered IBs did not cause any difficulties in mice mod-
els, even when administered in high doses [18].
In the presented work, we have studied the concept of
IBs as “nanopills” directly targeting the pathogen surface.
First, we demonstrated the basic principle regarding how
the tailored IBs are able to specifically recognise the adhe-
sins of pathogens attached to the tissues. Second, we
tested the release of indicator proteins representing thera-
peutic peptides from IBs. We compared the release of
soluble proteins from the IBs by protease or intein self-
cleavage under conditions of neutral and acidic pH values,
respectively. In addition to these results, we achieved the
reduction of hydrophobic interactions between the IB par-
ticles by the treatment with a polar amino acid.Results
Preparation and testing of tailored IBs
The first step in our work was the preparation of IBs-
conjugates representing “nanopills” composed of green
fluorescent protein (GFP)-containing IBs (gfpIBs) and
soluble proteins using glutaraldehyde as linker. GFP
represents a remedy whereas sialylated soluble protein is
expected to specifically recognise our model adhesin IBs
mimicking a pathogen. Non-sialylated proteins serve as
a control to prove the specificity of interactions dependent
on sialic acids.
For the optimisation of the conjugation reaction, the
gfpIBs were conjugated with the sialoprotein fetuin and
the non-sialylated protein albumin as a control. The pre-
pared conjugates were tested with the hemagglutination-
inhibition test. We used SabA lectin from the bacterium
Helicobacter pylori in the form of IBs (sabIBs) that is re-
sponsible for the in vitro agglutination of erythrocytes.
Because this interaction is dependent on the sialic acid
(Sia)-terminated oligosaccharides, it can be modified by
sialylated proteins [20], e.g., gfpIBs-fetuin conjugates. We
evaluated and compared the extent of the zone of positive
hemagglutination of the control and conjugate-testing
reactions. However, our results also showed the partial in-
hibition of hemagglutination by the gfpIB-albumin conju-
gates at higher concentrations, i.e., the restriction of the
zone of positive hemagglutination (Figure 1A). A compari-
son of the wells containing the sabIBs with the non-
conjugated gfpIBs and control wells containing only the
sabIBs revealed that the gfpIBs themselves (non-conju-
gated) inhibited the red-blood-cell (RBC) agglutination.
This inhibition is most likely caused by the hydrophobic
interactions between the sabIBs and the non-conjugated/
conjugated gfpIBs. Consequently, the ability of the sabIBs
to bind RBC decreased, which eliminated the prozone ef-
fect and increased the interval of negative agglutination
(see Figure 1A, compare line B and C). This problem has
been solved by the modification of the method used for
gfpIB conjugate preparation. The substitution of non-
polar glycine by polar lysine in the inactivation of residual
glutaraldehyde successfully reduced the hydrophobic ad-
hesion of the conjugated gfpIBs to the sabIBs, to each
other and to plastic surfaces. This reduction was reflected
by the lack of significant variability in the extent of the
positive hemagglutination zone (Figure 1B).
Once the optimisation was complete, we prepared the
gfpIBs conjugated with fetuin and with the non-sialylated
representative asialofetuin for further experiments. Test-
ing with the hemagglutination-inhibition assay confirmed
the accuracy of the prepared conjugates. The gfpIB-fetuin
conjugates inhibited the agglutination of RBC, which was
observed as the shortening of the zone of positive
hemagglutination compared with control wells. This in-
hibition was marked, especially at higher concentrations
Figure 1 The reduction of hydrophobic interactions between the conjugated GFP-containing IBs (gfpIBs) and the SabA adhesin
aggregated to IBs (sabIBs). A - gfpIBs conjugated with albumin using nonpolar glycine for glutaraldehyde inactivation. B - gfpIBs conjugated
with albumin using polar lysine for glutaraldehyde inactivation. Conjugates gfpIBs-albumin (1.25 mg of gfpIBs in 400 μl of PBS) were 1.5-fold
diluted from line H to D in 10 μl of PBS. The suspension of sabIBs (isolated from 10 mg of lyophilized transformed E. coli in 1000 μl of PBS,
diluted in ratio 1:16) was 1.5- (A) or 1.2-fold (B) serial diluted from column 1 to 12 in 15 μl of PBS. Finally, the wells were titrated with 50 μl of the
RBC suspension. Line A - negative control (RBC in PBS), Line B (green frame) - interaction of sabIBs with nonconjugated gfpIBs and RBC, Line C -
control interaction of sabIBs with RBC. Blue frame defines the zone of positive hemagglutination.
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tration, a modest extension was observed (Figure 2A).
In contrast, hemagglutination was not significantly
affected by the gfpIB-asialofetuin conjugates, as the
positive hemagglutination zone did not vary signifi-
cantly compared with control wells (Figure 2B).
In vitro visualisation of the specific recognition and
binding of tailored IBs to adherent pathogens
Our prepared conjugates representing “nanopills” suppose
to be capable to specifically target an adherent pathogen
cell in host organism. To visualise the recognition and
binding of these conjugates to pathogen adhesins, we
microscopically tested an in vitro model. We used the Sia-
binding adhesin SabA from Helicobacter pylori aggregated
to form IBs (sabIBs) which expose on the surface multipleFigure 2 The testing of the prepared gfpIB-fetuin (A) and gfpIB-asialo
extent of the positive hemagglutination zone. Hemagglutination-inhibi
(sabIBs with RBC, no conjugate), 2–6 – interaction of sabIBs with conjugate
conjugates is 1.5-fold increasing from 2 to 6.active binding centres. For this reason they are considered
as models of pathogen cells. Human stomach tissue is
represented by RBC that provide Sia-terminated oligosac-
charides on their surface for sabIB binding. Our tailored
IB conjugates represent potential particles for the specific
targeting of pathogen cells and the delivery of therapeutic
proteins. On the basis of results obtained by our testing,
we assigned the appropriate concentration of the sabIBs
and conjugates. Because our conjugates contain a green
fluorescent indicator protein, this interaction was detected
using fluorescent confocal microscopy. As seen in the
images (Figure 3), the erythrocytes are apparently clus-
tered around the aggregates of gfpIB-fetuin because the
sabIBs on their surface also simultaneously interact with
the Sias of fetuin in the tailored IBs (Figure 3A). In the
case of gfpIB-asialofetuin, the erythrocytes with boundfetuin (B) conjugates by the evaluation of their impact on the
tion assay was designed as for optimization (Figure 1). 1 – control
s and RBC; concentration of gfpIB-fetuin and gfpIB-asialofetuin
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without any evidence of being clustered inside the aggre-
gates. Asialofetuin does not contain any Sias; thus, there is
no multiple-specific interaction observed between ery-
throcytes and conjugates (Figure 3B).
A remedy released from inclusion bodies
Firstly, our goal was to demonstrate the release kinetics
governed by the two model self-cleaving modules under
two model pH conditions. To explore more precisely pos-
sibilities of the release regulation, we tested the release po-
tential of “remedy-carrying” compounds of unconjugated
IBs. Thus, we eliminated any factors (e.g. soluble parts of
conjugates) that might bring additional complications by
influencing the release kinetics and their primary com-
parison. For this purpose, we tested two unconjugated
constructs: CBDclos-SrtA-GFP and CBDclos-intein-GFP,
despite the fact that conjugated CBDclos-intein-GFP IBs
– gfpIBs were used in previous sections. The cellulose-
binding domain from Clostridium cellulovorans (CBDclos)
serves as a 20 kDa “pull-down domain” that pulls down
expressed proteins, changing them from a soluble to an
insoluble form while maintaining the activity of the fused
protein [12]. The GFP represents the potential remedy
which should be released from the particles. It was chosen
to achieve better visualisation and measurement of the
process (Figure 4A, inset). Staphylococcus aureus sortase
A (SrtA) and Ssp DNAB intein were inserted between the
CBDclos and GFP and serve as cleaving modules; both are
capable of cleaving the protein chain at its C-terminus
and release the otherwise soluble GFP. SrtA is protease
specific for the LPXTG amino acid sequence and needs
Ca2+ ions for optimal activity [21]. The Ssp DNAB intein
from Synechocystis sp. has temperature- and pH-dependent
self-cleavage activity at its C-terminus [22]. These fusion
proteins were designed for fast, medium, slow and very
slow activities. Figure 4 shows the fast (pH 7, activated by
Ca2+) and medium (pH 7) releases, which can be counted
in minutes. Interestingly, the time course of the relativeFigure 3 Images of the in vitro model of the specific interactions of th
fetuin (green fluorescent particle) are surrounded by erythrocytes carrying
agglutinates. B) Aggregates of gfpIBs-asialofetuin (green fluorescent parti
C) Control represented by erythrocytes in PBS; For better visualization, thefluorescence intensity was “slower” than the measured pro-
tein concentration in the supernatant, indicating that GFP
folding is completed after its release into the solution.
According to the potential application for the targeting of
bacterial cells in the stomach, the activity was tested at an
acidic pH (2.5). In this case, SrtA showed moderate activity
but was still active. The GFP release was quite slow and,
for this reason, can be counted in hours. The GFP was not
capable of fluorescence at pH 2.5; therefore, the released
protein was monitored only by its protein concentration in
the supernatant (Figure 4B). The CBDclos-intein-GFP pro-
tein aggregates showed very weak cleavage efficiency; the
time course was measured in weeks (Figure 5). Both types
of physiologically aggregated constructs were dissolved in
1% SDS and the protein concentration was measured using
a modified biuret reagent for the Lowry procedure (TP0200
and B 3934, Sigma, Germany). According to the soluble pro-
tein concentrations shown in the graphs (Figures 4 and 5),
the CBDclos-SrtA-GFP protein aggregates released a ma-
ximum of 10.7% whole aggregated protein in 90 minutes,
while the CBDclos-intein-GFP protein aggregates released
11.8% whole aggregated protein in 8 weeks.
Discussion
In this work, we present proof of principle of a novel direc-
tion of protein drug delivery in medicine. Our experimen-
tal results show that correctly tailored IBs could be cheap
protein cassettes for protein drug delivery that are able to
specifically attack pathogen adhesins or receptors of differ-
ent tissue. Additionally, the tailored IBs are able to carry
and release a protein in “programmable” time courses.
Our tailored IBs were prepared via a conjugation reac-
tion using glutaraldehyde. The IBs containing the indicator
protein GFP (CBDclos-intein-GFP) were linked to a sialy-
lated and non-sialylated protein, respectively. To test this
reaction, the resulting conjugates were tested using our
method based on the hemagglutination-inhibition assay
[20]. The Sia-dependent hemagglutination is expected to
be inhibited by the conjugates containing fetuin bute tailored IBs with adherent pathogens. A) Aggregates of gfpIBs-
SabA adhesin in form of IBs (sabIBs) on their surface – inside of the
cle) are just randomly attached to erythrocytes with bound sabIBs.
micrographs show clusters of gfpIBs particles.
Figure 4 GFP released from the inclusion bodies composed of the CBDclos-SrtA-GFP fusion protein. A) Fluorescence of soluble protein
released from IBs under neutral pH. The inset shows colors of supernatant and sediment before (on the right) and after (on the left) release. RFI -
relative fluorescence intensity B) Concentration of soluble protein released from IBs under acidic and neutral pH. Total concentration of the
CBDclos-SrtA-GFP fusion protein was 5.42 mg/ml.
Talafová et al. Microbial Cell Factories 2013, 12:16 Page 5 of 9
http://www.microbialcellfactories.com/content/12/1/16unaffected by the asialofetuin conjugates. However, be-
cause the hemagglutination was evoked by the SabA
adhesin in the form of IBs, the hydrophobic interactions
between the sabIBs and gfpIBs, apparently also between
sabIB and gfpIB conjugates, misrepresented the results
of our test. Generally, bacterial IBs, as opposed to sol-
uble globular proteins, represent physiological aggregatesFigure 5 GFP released from the inclusion bodies composed of the CB
intein-GFP fusion protein was 6.86 mg/ml.composed mainly of recombinant proteins in the form of
an unfinished tertiary structure; therefore, more hydro-
phobic acids are exposed on the water-protein interface,
thereby allowing themselves IBs formation and clustering
IBs to large clusters by hydrophobic interactions. In other
words, the ratio of the burial of hydrophobic residues
from water balances the aggregate stability and enzymeDclos-intein-GFP fusion protein. Total concentration of the CBDclos-
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module provides the maximal hydrophobic interaction
among fusion protein molecules and forms maximally
stable aggregates, and the cleaving module, together with
GFP, form the maximal globule stage and provide the
maximal activity. However, the hydrophobic interactions
between the sabIBs and gfpIBs were not desired; therefore,
we decided to change the amino acid used for glutaralde-
hyde inactivation in the preparation of the gfpIB conjugates.
Glutaraldehyde reacts very well with various amino acids
[23]; thus, they are used as deactivators of un-reacted glu-
taraldehyde [24,25]. For our conjugation reaction, glycine
was the first choice for the glutaraldehyde inactivation be-
cause it is a small neutral amino acid without any signifi-
cant effects on the intramolecular hydrophobic interactions
[26]. After observing the unwanted hydrophobic interac-
tions between the sabIBs and conjugates, we applied an ex-
cess of lysine to eliminate the un-reacted glutaraldehyde.
Lysine is largely polar [26], and treatment with it “polarised”
the surface of the IBs and successfully eliminated the
hydrophobic interactions between the sabIBs and gfpIB
conjugates as well as between the gfpIBs and plastic sur-
faces. After applying this approach, our test confirmed
the specificity of the Sia-dependent interactions be-
tween erythrocytes, sabIBs and conjugates. As expected
on the basis of on our previously published results
[20,27], the fetuin-containing conjugates modified the
level of hemagglutination, whereas the asialofetuin-
containing conjugates maintained the hemagglutination
level similar to control wells.
The specificity of the interactions was also confirmed
by our in vitro model. We selected the pathogenic bac-
terium Helicobacter pylori and its SabA adhesin as a
model for our study. The SabA adhesin has been well-
studied in the pathogenesis of H. pylori. Because it
recognises Sias, it binds the sialylated antigens on the
inflamed gastric epithelium and on RBC in gastric mu-
cosal blood vessels [3,4]. SabA aggregated to form IBs is
substituting pathogen cells in our model. Under a fluor-
escent confocal microscope, it was confirmed that only
the tailored IBs containing fetuin strongly interacted
with the pathogen cells (represented by sabIBs) bound
to the Sias on the erythrocyte surface. The conjugates
containing asialofetuin did not show the same interac-
tions under the same conditions. The conjugates used
for this experiment were compressed into a pellet due to
centrifugation and resuspension of the pellet with a pip-
ette resulted in the formation of smaller clusters. These
clusters were used for the microscope reaction due to
better visibility. However, the basic concept is the appli-
cation of the IBs as “nanopills” for biomedicine. Several
works have been already published, demonstrating that
IBs are mechanically stable enough to tolerate the ultra-
sonication needed to obtain IBs with a median sphericaldiameter of 200–500 nm [28,29]. Thus, conjugates could
be very easily broken into nanoparticles via sonication.
Our results provide convincing evidence that tailored IBs
are potentially able to specifically target adherent patho-
gen cells on human tissues. Erythrocytes in our in vitro
model underwent some morphological changes compared
to control erythrocytes in neutral phosphate buffer. RBC
are very susceptible to the environment changes, and the
transformation of their shape might be caused by various
aspects [30]. We suggest that morphological changes are a
consequence of binding of sabIBs to the Sias on the cell
surface. However, this has no significant impact on our
results, as this shape modification was observed in a
model of the interaction of RBC-sabIBs with gfpIB-fetuin
as well as with gfpIB-asialofetuin.
The other part of this study focused on demonstrating
the drug release from gfpIBs. The therapeutic protein is
represented by GFP, the release of which was tested under
two pH conditions. Neutral pH (pH 7.0) was chosen as
the primary condition under which also specific pathogen
recognition in vitro was demonstrated. However, the pH
values in the human body vary widely. Because a model
adhesin for our recognition study was SabA from H. pyl-
ori, a bacterium colonising stomach, we decided to test
also protein release under acidic pH conditions (pH 2.5).
The GFP remains fluorescently active when aggregated
into the IBs, as was demonstrated by fusion to the VP1
capsid protein of the foot-and-mouth disease virus [11].
We used the CBDclos system that initiates the physio-
logical aggregation of GFP and also maintains protein ac-
tivity. As a cleaving module, we used the S. aureus sortase
A (SrtA) and Ssp DNAB intein from Synechocystis sp. SrtA
has already proven to be an efficient tag for the purifica-
tion of recombinant proteins when fused to their N-
termini [21,31] but, until now, was not applied to the
protein release from IBs. Our results show that the SrtA
protease is capable of effectively releasing the protein from
IBs at a neutral pH in a relatively short period of time. At
an acidic pH, such as in the stomach, the progress of GFP
release was markedly slower compared to that observed at
neutral pH. Nevertheless, the very slow (several weeks
lasting) release of the proteins was observed in the aggre-
gates containing intein as the cleaving module. The Ssp
DNAB intein was tested as a part of the potential cleav-
able self-aggregating tag, indicating the aggregation of the
target proteins to form IBs and the subsequent intein-
cleavage and release of soluble protein. However, the
cleavage efficiency of this intein was marked as insuffi-
cient; thus, it was not tested further [32]. Although its
cleavage activity is not suitable for protein purification,
this intein might be beneficial for biomedical purposes, as
its sustained, long-lasting drug release might be desirable
in some cases, such as in the treatment of chronic diseases
[33]. In contrast, the treatment of some infections requires
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sequential drug release over several minutes to hours.
And this can be achieved by the protease cleavage activity.
Nowadays, various mechanisms of controlled drug release
are described and their application depends on the way of
administration as well as the type of infection. However,
novel concept of nanocarriers enabling the drug targeting
to specific cells is considered as very beneficial [35].
Conclusions
The results presented here, combined with the knowledge
of pathogen adhesins, can provide an effective tool for dir-
ect pathogen targeting with therapeutic substances. IBs
are currently considered to be promising nanoparticles for
biomedical purposes. The tailored IBs used in this study
were composed of indicator proteins aggregated to form
IBs that were conjugated with soluble proteins responsible
for pathogen recognition. The indicator proteins forming
the IBs represented a remedy. The conjugates during
preparation were treated with a polar amino acid to avoid
the hydrophobic interactions between the IBs in subse-
quent experiments. The results confirmed our hypothesis
that the IBs are able to specifically recognise and bind to
the surface of adherent pathogens. The use of two self-
cleaving modules, protease and intein, also demonstrated
that the indicator proteins forming the IBs can be effi-
ciently released from the IBs and thus converted from an
insoluble into a soluble form. The protease provided fast
protein release, taking from several minutes to hours
depending on the conditions, whereas the intein-cleaving
module enabled a sustained protein release over several
weeks. The model proposed here represents a promising
advance in biomedicine, introducing IBs as potential
“nanopills” able to specifically attach to pathogen adhesins
and subsequently release a remedy. Each of the two tested
self-cleaving modules provides a different pace of remedy
release that might be chosen depending on the particular
infection.
Material and methods
Cloning, expression and isolation of SabA adhesin
aggregated to form IBs (sabIBs)
The method described by Nahalka et al. (2009) [27] was
used for the production of SabA lectin in the form of ac-
tive IBs. IBs were isolated from Escherichia coli BL21
(DE3) transformed by plasmid vector pET-34b(+). The in-
sert carried by vector was truncated gene HP0662 isolated
from genomic DNA of Helicobacter pylori ATCC700824D.
This gene was inserted in such a way that N-terminus of
the resulted protein was fused with the cellulose-binding
domain of C. cellulovorans (CBDclos). The described fu-
sion initiated physiological aggregation of the protein into
the active IBs. Transformed E. coli was cultivated in LB
medium (10 g/l trypton, 5 g/l yeast extract, 10 g/l NaCl)with kanamycine (30 μg/ml). After cultivation, the cells
were lyophilized. IBs were isolated from 10 mg of lyophi-
lized cells using 500 μl of non-ionic lytic detergent (Sigma,
B7435-500ML). The lysate was subsequently centrifuged
(13000 g, 10 min., 4°C) and washed three times in 750 μl
Tris–HCl (50 mM, pH 7.5). Finally, the pellet was sus-
pended in 1 ml of PBS (0.8% NaCl, 0.02% KCl, 0.115%
Na2HPO4x7H2O, 0.02% KH2PO4, pH 7.2).Cloning, expression and isolation of Staphylococcus
aureus sortase A plus GFP and Ssp DNAB intein plus GFP
aggregated to form IBs (gfpIBs)
The GFP gene was amplified by PCR from TurboGFP
plasmid purchased from EVRΩGEN. Staphylococcus aur-
eus sortase A (SrtA) and Ssp DNAB intein (intein) genes
were artificially synthesized by GenScript Corporation.
The AGGCCT restriction places for StuI enzyme have
been attached to the C-terminus of synthesized genes.
The synthetic genes were inserted into pET-34b(+) plas-
mid, the constructs were linearized by StuI enzyme, and
subsequently, GFP sequence has been inserted to the vec-
tors by LIC method. As the result, constructs for the ex-
pression of CBDclos-SrtA-GFP and CBDclos-intein-GFP
fusion proteins were obtained. CBDclos-SrtA-GFP fusion
protein contained KKLPETGR linker sequence inserted
between SrtA and GFP. The cultivation of transformed
Escherichia coli BL21(DE3) and the isolation of IBs were
performed as mentioned above, but in the case of
CBDclos-SrtA-GFP fusion protein, 15 mM EDTA was
added to lytic detergent and washing buffer.Preparation of fetuin-glutaraldehyde-IBs conjugate
A glycoprotein fetuin (Mw = 48.4 kDa) (Sigma, F2379-
1 G), asialofetuin (Sigma, A4781-250MG) or albumin
(Sigma, A4503-10 G) (both reference samples) – 25 mg/
250 μl – were conjugated via glutaraldehyde (GAL;
0.25%) with IBs. IBs were, prior to reaction, prepared as
above-mentioned in the suspension concentration of
1.25 mg/375 μl (PBS; pH 7.2). IBs-GAL conjugate was
prepared as follows: a cooled stock GAL solution was
gradually added in 10 μl aliquots under stirring (by pip-
ette) in 10-min intervals during the 1st h to achieve a
final GAL concentration of 0.25% and final volume
435 μl. The whole reaction time was 2 h/+4°C. Fetuin
was under intensive stirring quickly dissolved in the
reaction system. The reaction proceeded 1 h/+4°C. The
same procedure was performed applying asialofetuin or
albumin. An amino acid – L-glycine or L-lysine (to
achieve 100 mM in final volume 485 μl) was added at the
end of the conjugation reaction (blocking the unreacted
-CHO groups). A molar concentration ratio of amino
acid/GAL was ~ 3.8. The system was then left to stand at
+4°C until next day. It was finally washed and centrifuged
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erythrocytes and sabIBs.
Testing of tailored IBs
Prepared conjugates gfpIBs-fetuin/gfpIBs-asialofetuin or
gfpIBs-albumin were resuspended in 400 μl of PBS. First,
the conjugates gfpIBs-fetuin and gfpIBs-albumin were
tested just to optimize conjugation reaction. After
optimization, the conjugates gfpIBs-fetuin and gfpIBs-
asialofetuin were prepared and tested. The method used
for testing is based on hemagglutination-inhibition test
and was described by Talafová and Nahálka (2012) [20].
The conjugate suspension was 1.5-fold diluted in 10 μl
of PBS in microtiter plate from line H to D. The suspen-
sion of sabIBs was diluted in ratio 1:16, the resulting sus-
pension was 1.5- or 1.2-fold serial diluted in PBS and
added to conjugates in volume of 15 μl. Finally, the mix-
ture was titrated with 50 μl of the RBC suspension (50 μl
of fresh human blood in 5 ml of PBS). RBC were voluntar-
ily donated by one of the authors (KT). The RBC suspen-
sion in PBS was considered as a negative control. The
other controls contained RBC suspension with (i) sabIBs
and nonconjugated gfpIBs or (ii) sabIBs alone. The micro-
titer plate was incubated for 1 hour at room temperature
and subsequently 2 hours at 4°C. After incubation, elec-
tronic record was used to compare tested samples with
control wells.
In vitro visualisation of specific recognition and binding
of tailored IBs to adherent pathogen
RBC suspension (500 μl) was mixed with 150 μl of sabIBs
suspension diluted in ratio 1:32 and additional 100 μl of
PBS. After short gentle shaking, RBC were allowed to
sediment. After supernatant removal, the sediment was
washed twice with PBS, suspended in 500 μl of PBS and
mixed with 66.7 μl of the suspension of conjugate IBs-
fetuin or IBs-asialofetuin, and additional 183.3 μl of PBS
by gentle shaking. RBC were allowed to sediment, and
after supernatant removal, they were washed twice with
PBS. Finally, the sediment was suspended in 500 μl of PBS
and observed by fluorescent confocal microscopy. RBC
were voluntarily donated by one of the authors (KT).
Soluble protein release from unconjugated gfpIBs
IBs composed from CBDclos-SrtA-GFP fusion protein
were resuspended in the 50 mM phosphate buffer
(5.42 mg/ml) alternatively containing 2 mM Ca2+ (pH 7.0)
or 5 mM Ca2+ (pH 2.5), and IBs composed from CBDclos-
intein-GFP fusion protein were resuspended in the 50 mM
Tris buffer (6.86 mg/ml, pH 7.0). The stock suspension
was divided into equal parts which were kept at +4°C be-
fore withdrawal to determine time-course of the soluble
protein release. The samples were withdrawn and centri-
fuged in time-intervals depicted in Figures 4 and 5. Eachpoint was evaluated in triplicate. RFI (excitation wave-
length 482 nm; emission wavelength 502 nm) and A280
values were obtained using Fluorimeter (BioTek FLx
800TM Multi-Detection Microplate Reader, Germany) and
Spectrophotometer (Infinite M200 TECAN, Switzerland).
Fluorescence was not measured at the acidic pH, because
IBs became colorless.
A colorimetric method utilizing Total Protein Kit
composed of Biuret Reagent and Folin and Ciocalteu’s
Phenol Reagent was used to determine soluble protein
concentration (mg/ml) in the supernatant (TP0200 and
B 3934, Sigma, Germany). Absorbance at 750 nm was
obtained spectrophotometrically, and the protein con-
centration was plotted against the time. A total protein
concentration of the IBs at the time t0 was evaluated
after dissolving in 1% SDS. However, it is worth of no-
ticing that the CBDclos-intein-GFP-containing IBs were
less easily soluble in 1% SDS – prepared in 0.85% NaCl
– than the CBDclos-SrtA-GFP-containing IBs.
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